Escitalopram for agitation in Alzheimer's disease (S‐CitAD): Methods and design of an investigator‐initiated, randomized, controlled, multicenter clinical trial
Abstract
Alzheimer's disease (AD) is a disabling, common cause of dementia, and agitation is one of the most common and distressing symptoms for patients with AD. Escitalopram for agitation in Alzheimer's disease (S‐CitAD) tests a novel, clinically derived therapeutic approach to treat agitation in patients with AD.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 03, 2019
- Source ID
- 10.1016/j.jalz.2019.06.4946
Entities
People
- Anton P. Porsteinsson
- Bruce G. Pollock
- Constantine G. Lyketsos
- Cynthia A. Munro
- Davangere P. Devanand
- David M. Shade
- Dimitri Avramopoulos
- Jacobo Mintzer
- Lea T. Drye
- Lon S. Schneider
- Paul B. Rosenberg
- Sheriza N. Baksh
- Stephan Ehrhardt
- S‐citad Research Group
- Tarek K. Rajji
- Zahinoor Ismail
Organizations
- Columbia University
- Johns Hopkins Bloomberg School of Public Health
- Johns Hopkins University
- Medical University of South Carolina
- University of Calgary
- University of Rochester
- University of Southern California
- University of Toronto